Clinical Significance of Hepsin and Underlying Signaling Pathways in Prostate Cancer

Clinical Significance of Hepsin and Underlying Signaling Pathways in Prostate Cancer

The hepsin gene encodes a type II transmembrane serine protease. Previous studies have shown the overexpression of hepsin in prostate cancer, and the dysregulation of hepsin promotes cancer cell proliferation, migration, and metastasis in vitro and in vivo. The review incorporated with our work show...

Full description

Bibliographic Details
Main Authors:	Lucy Lu, Adam Cole, Dan Huang, Qiang Wang, Zhongming Guo, Wancai Yang, Jim Lu
Format:	Article
Language:	English
Published:	MDPI AG 2022-01-01
Series:	Biomolecules
Subjects:	hepsin prostate cancer metastasis survival biomarker target
Online Access:	https://www.mdpi.com/2218-273X/12/2/203

Similar Items

Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients
by: David Zaragoza-Huesca, et al.
Published: (2022-06-01)

Hepsin immunohistochemical expression in prostate cancer in relation to Gleason′s grade and serum prostate specific antigen
by: Madhu Mati Goel, et al.
Published: (2011-01-01)

Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells
by: Maria Carmen Rodenas, et al.
Published: (2023-05-01)

Design of drug-like hepsin inhibitors against prostate cancer and kidney stones
by: Vincent Blay, et al.
Published: (2020-07-01)

The serine protease hepsin mediates urinary secretion and polymerisation of Zona Pellucida domain protein uromodulin
by: Martina Brunati, et al.
Published: (2015-12-01)

Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin
by: David Zaragoza-Huesca, et al.
Published: (2023-12-01)

A High-Affinity <sup>64</sup>Cu-Labeled Ligand for PET Imaging of Hepsin: Design, Synthesis, and Characterization
by: Ji-Hun Park, et al.
Published: (2022-09-01)

Pretreatment neutrophil‐to‐lymphocyte ratio as a potential prognostic biomarker for newly diagnosed patients with metastatic castration‐sensitive prostate cancer
by: Samer Salah, et al.
Published: (2021-10-01)

Classification between normal and tumor tissues based on the pair-wise gene expression ratio
by: Wong YC, et al.
Published: (2004-10-01)

Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers
by: Shoichiro Mukai, et al.
Published: (2020-04-01)

High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific Mortality
by: Charles Dariane, et al.
Published: (2022-03-01)

Anti-Tumor Functions of Prelatent Antithrombin on Glioblastoma Multiforme Cells
by: Julia Peñas-Martínez, et al.
Published: (2021-05-01)

The Impact of the Percent of Residual Prostate-Specific Antigen on Metastasis-Free Survival in Patients with Persistent Prostate-Specific Antigen after Radical Prostatectomy
by: Dan Bee Lee, et al.
Published: (2023-01-01)

Specific classification and new therapeutic targets for neuroendocrine prostate cancer: A patient-based, diagnostic study
by: YouZhi Wang, et al.
Published: (2022-09-01)

The prostate tissue‐based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy
by: Christopher M Heaphy, et al.
Published: (2022-09-01)

Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer
by: Konrad Sopyllo, et al.
Published: (2021-02-01)

βKlotho Inhibits Cell Proliferation by Downregulating ELK4 and Predicts Favorable Prognosis in Prostate Cancer
by: Mao C, et al.
Published: (2021-08-01)

Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels
by: Kyo Chul Koo, et al.
Published: (2015-03-01)

Adult primary prostate sarcoma: A multi-center cohort study and comparison between Chinese and American cases
by: Beichen Ding, et al.
Published: (2021-01-01)

Systematic review and integrated analysis of prognostic gene signatures for prostate cancer patients
by: Yang An, et al.
Published: (2023-12-01)

Clinical characteristics and survival outcomes in patients with a high PSA and non-metastatic prostate cancer
by: Cheng-Yu Huang, et al.
Published: (2022-01-01)

Incidence trends and survival of metastatic prostate cancer with bone and visceral involvement: 2010-2019 surveillance, epidemiology, and end results
by: Gaohaer Kadeerhan, et al.
Published: (2023-08-01)

Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial
by: Byung Ha Chung, et al.
Published: (2022-01-01)

Exploring the Wnt Pathway as a Therapeutic Target for Prostate Cancer
by: Sarah Koushyar, et al.
Published: (2022-02-01)

ZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer
by: Manuela Montanaro, et al.
Published: (2023-03-01)

The Emerging Role of Circular RNAs in Prostate Cancer: A Systematic Review
by: Fan Chao, et al.
Published: (2021-07-01)

Type II Transmembrane Serine Proteases as Modulators in Adipose Tissue Phenotype and Function
by: Qingyu Wu, et al.
Published: (2023-06-01)

Differentially Expressed Genes and Molecular Pathways in an Autochthonous Mouse Prostate Cancer Model
by: Shiv Verma, et al.
Published: (2019-03-01)

Can We Predict Prostate Cancer Metastasis Based on Biomarkers? Where Are We Now?
by: Ignacio F. San Francisco, et al.
Published: (2023-08-01)

Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer
by: Maria Frantzi, et al.
Published: (2020-08-01)

Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer
by: Wojciech A. Cieślikowski, et al.
Published: (2023-03-01)

Research Progression in the Mechanism of Bone Metastasis and Bone-Targeted Drugs in Prostate Cancer
by: Sajjad Ahmad
Published: (2024-02-01)

Comparative Proteomics Uncovers Correlated Signaling Network and Potential Biomarkers for Progression of Prostate Cancer
by: Jianzhong Ai, et al.
Published: (2017-01-01)

Enhancing androgen ablation response in metastatic hormone-sensitive prostate cancer: the benefits of transurethral resection of the prostate
by: Yan Zhao, et al.
Published: (2023-07-01)

Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer
by: Francesco Lasorsa, et al.
Published: (2023-01-01)

A gene prognostic index from cellular senescence predicting metastasis and radioresistance for prostate cancer
by: Dechao Feng, et al.
Published: (2022-06-01)

Recent Advances in Advance Prostate Cancer
by: Nishant Lohia
Published: (2022-12-01)

The Prognostic Value of PI-RADS Score in CyberKnife Ultra-Hypofractionated Radiotherapy for Localized Prostate Cancer
by: Marcin Miszczyk, et al.
Published: (2022-03-01)

Association of adenosine signaling gene signature with estrogen receptor-positive breast and prostate cancer bone metastasis
by: Daniel Brian Shropshire, et al.
Published: (2022-09-01)

Limitations of Explainability for Established Prognostic Biomarkers of Prostate Cancer
by: Kalifa Manjang, et al.
Published: (2021-07-01)